FDA updates Zytiga label with OS results; FDA reviewers back Medicines Co. clot preventer;

> The FDA has approved a label update for Johnson & Johnson's ($JNJ) Zytiga that includes overall survival results in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Release

> FDA reviewers have recommended that the agency approve The Medicines Company's ($MDCO) once-rejected blood clot preventer. Report

> European payers are still the most important targets of health economics and outcomes research when it comes to getting a product onto formularies, new research shows. Release

> Roche ($RHHBY) aims to have an immunotherapy cancer drug in 11 late-stage trials by the end of the year. Report

> Specialty dermatology drugmaker Cipher Pharmaceuticals has acquired Innocutis Holdings, the licensee of Sitavig, in the U.S. Release

> IBM ($IBM) is growing its presence in healthcare with the rollout of the Watson Health unit, extending its partnership with Apple and inking deals with Johnson & Johnson and Medtronic ($MDT). More

And Finally... AstraZeneca ($AZN), looking to bring patient-centric evidence into drug discovery and development, has signed a 5-year deal with PatientsLikeMe for access to the network's 325,000-plus members. More

Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.